Biosenta Inc
CCSE:ZRO0.08
CAD
+0.04
(+100.00%)
ISIN
CA09072N2023
CUSIP
09072N202
Return %
Stock
S&P 500
1Y
-36.00
14.20
3Y
-79.75
81.12
5Y
-78.95
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Amarvir Singh Gill
- Full Time Employees
- 5
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- 18 Wynford Drive Rocky View County ON Canada M3C 3S2
- IPO Date
- Sep 22, 2005
- Website
- biosenta.com
- Similar Companies
- Business
- Biosenta Inc. is a Canadian innovator specializing in the development, manufacture, and commercialization of advanced antimicrobial products designed for household and industrial applications. The company’s core product offerings include Tri-Filler®, a proprietary core-shell calcium hydroxide-calcium carbonate (CSCC) nanoparticle technology that provides long-lasting antimicrobial protection against a broad spectrum of bacteria, molds, fungi, and viruses, and true™, a Health Canada-recognized broad-spectrum, anti-microbial, dual-action disinfectant initially developed for COVID-19 mitigation. Biosenta’s technologies aim to offer environmentally responsible solutions addressing the global health challenge of antimicrobial resistance. Founded in 1986 and headquartered in Toronto, Ontario, the company operates primarily in Canada with expanding global ambitions. Recent major developments at Biosenta include the successful launch and operation of a benchmark bench-scale production facility that notably exceeds expectations with a production capacity of 170 kilograms per day, establishing a foundation for scaling to commercial production. The company has advanced its manufacturing inputs by integrating food-grade calcium hydroxide and industrial-grade carbon dioxide, enhancing sustainability while reducing production costs without sacrificing product efficacy. Biosenta also entered a strategic licensing agreement with Lightweight Concrete Solutions, granting them exclusive rights to use Biosenta’s Tri-Filler® technology in specialty concrete products, further expanding market reach and revenue streams. Additionally, the company strengthened its advisory board with industry veterans such as Gary LeRoux, former President and CEO of the Canadian Coatings Association, and executed private placement financings to support future growth initiatives. Biosenta has also progressed in research collaborations, notably with Dr. Ian Lewis and Dr. Maen Husein’s laboratories, confirming the breakthrough antimicrobial efficacy of its Tri-Filler® nanoparticles through peer-reviewed studies. Biosenta’s product portfolio spans chemical compounds for antimicrobial disinfection and material enhancement, targeting diverse sectors including household cleaning, industrial applications, and specialty materials manufacturing. The company is focused on commercializing next-generation antimicrobial technologies to capture expanding markets driven by the global need for effective, sustainable antimicrobial solutions. It leverages innovative nanotechnology and chemical compounds to provide durable protection and improve material performance with reduced environmental impact. Biosenta is publicly traded on the Canadian Securities Exchange under ticker ZRO.CN, reflecting its status as a growing player in the chemical and antimicrobial technology industry.
Company News
Biosenta Commences TRUE(TM) Testing with Dynamic Facility Services
Biosenta Enters into Memorandum of Understanding with Dynamic Facility Services for TRUE(TM) Pilot Program
Secretary of State Randeep Sarai Visits University of Calgary to Learn About Biosenta's Tri-Filler(TM) Technology
Biosenta Highlights Independent University of Calgary Research Validating Tri-Filler(TM) Antimicrobial Technology